Skip to main content
Gary Schwartz, MD, Oncology, New York, NY

GaryKSchwartzMD

Oncology New York, NY

Professor of Medicine Chief, Division of Hematology/Oncology Columbia University Irving Medical Center Deputy Director, Herbert Irving Comprehensive Cancer Center

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schwartz's full profile

Already have an account?

  • Office

    161 Fort Washington Ave
    New York, NY 10032
    Phone+1 212-305-5098

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1986 - 1988
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1986
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1983 - 1984
  • Albany Medical College
    Albany Medical CollegeClass of 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • NY State Medical License
    NY State Medical License 1984 - 2025
  • OH State Medical License
    OH State Medical License 2023 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Sorafenib for Advanced and Refractory Desmoid Tumors  
    Gary Schwartz, MD, The New England Journal of Medicine

Press Mentions

  • Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq Trial
    Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq TrialMarch 9th, 2023
  • Angiosarcoma Research Project Produces Windfall of Druggable Insights
    Angiosarcoma Research Project Produces Windfall of Druggable InsightsApril 8th, 2020
  • Six Columbia Cancer Researchers Receive Seed Funding from Velocity
    Six Columbia Cancer Researchers Receive Seed Funding from VelocityJuly 15th, 2019
  • Join now to see all

Grant Support

  • P2 - Developing New Strategies For Targeting Pdgfr/Pi3k/Akt Pathways In SarcomaNational Cancer Institute2010–2011
  • Developing New Strategies For Targeting Mtor And Igf-1r/Pi3k/Akt Pathways In SarcNational Cancer Institute2009–2011
  • Translational Research Studies In Clinical Trials Of Novel Therapeutics For SarcoNational Cancer Institute2010
  • Phase II Study Of Imatinib Mesylate In Patients With Inoperable MelanomaFood And Drug Administration2008–2010
  • Mskcc Clinical Oncology Research Career Development ProgramNational Cancer Institute2006–2010
  • Laboratory &Clinical Develpmt Of Cell Cycle Active Agents In The Treatmt Of STSNational Cancer Institute2006–2010
  • Clinical Trials Of Flavopiridol With ChemotherapyNational Cancer Institute2001–2008
  • Phase I Trial Of Safingol And CisplatinNational Cancer Institute2005–2006
  • Genetics Of Low Renin HypertensionNational Center For Research Resources2005
  • Mentoring For New Cancer TherapeauticsNational Cancer Institute2001–2005
  • Drg1: A Novel Molecular Target For Cancer TherapyNational Cancer Institute2002
  • Protein Kinase C--A Novel Target For Cancer TherapyNational Cancer Institute1996–2000
  • Core--BioenergeticsNational Heart, Lung, And Blood Institute1998